By Katryna Perera ( May 6, 2026, 4:45 PM EDT) -- Alto Neuroscience has urged a California federal judge to toss an investor suit alleging the psychiatric biotech company and its top brass overstated the efficacy of their lead drug candidate for treating major depressive disorder, saying the suit is a "classic case of trying to plead fraud by hindsight."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.